Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancerKUKIS, David L; NOVAK-HOFER, Ilse; DENARDO, Sally J et al.Cancer biotherapy & radiopharmaceuticals. 2001, Vol 16, Num 6, pp 457-467, issn 1084-9785Article

Combined modality radioimmunotherapy: Promise and perilBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer. 2002, Vol 94, Num 4, pp 1320-1331, issn 0008-543X, SUPConference Paper

Radioimmunotherapy with ¹¹¹in/⁹⁰y-2it-BAD-m170 for metastatic prostate cancerO'DONNELL, Robert T; DENARDO, Sally J; MIRICK, Gary R et al.Clinical cancer research. 2001, Vol 7, Num 6, pp 1561-1568, issn 1078-0432Article

Metabolite production in patients with lymphoma after radiometal-labeled antibody administrationDENARDO, Gerald L; DENARDO, Sally J; KUKIS, David L et al.The Journal of nuclear medicine (1978). 2001, Vol 42, Num 9, pp 1324-1333, issn 0161-5505Article

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to lndium-111 /yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibodyRICHMAN, Carol M; DENARDO, Sally J; KUKIS, David L et al.Clinical cancer research. 2005, Vol 11, Num 16, pp 5920-5927, issn 1078-0432, 8 p.Article

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of ⁹⁰Y-DOTA-peptide-Lym-1 in lymphoma xenograftsTUSCANO, Joseph M; O'DONNELL, Robert T; MIERS, Laird A et al.Blood. 2003, Vol 101, Num 9, pp 3641-3647, issn 0006-4971, 7 p.Article